You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201521 - 201530 of 207728 results
  1. Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV

    SBC: GLSynthesis Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is no cure for herpes simplex virus (HSV) latent infections of neurons, and the possibility of asymptomatic reactivation and simultaneous transfer of infectious virus via mucous membranes is a significant drawback of current therapies. We have pioneered the study of selective inhibitors of the herpes virus-specific thymidine kinase (TK), the enzyme re ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of a new VL vaccine candidate in dogs that significantly protects mice

    SBC: DETECTOGEN INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The long-term goal of this research program is to validate in dogs a candidate vaccine against visceral leishmaniasis (VL) for evaluation in future clinical evaluations. We have recently described a powerful and reliable antigen discovery strategy to directly identify microbial vaccine candidate antigens in human bodily secretions. We combined RP-HPLC and mass ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of novel pyranopyridine efflux pump inhibitors

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Infections caused by multi-drug resistance (MDR) Gram-negative pathogens are becoming increasingly difficult to treat, resulting in increased frequency of treatment failure and mortality. The increasing prevalence of MDR Gram-negative pathogens presents an unprecedented clinical challenge that requires innovative strategies for dealing with infections caused by ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall objective of this project is to generate new, potent, selective antimalarials that act through a novel mechanism of blocking the plasmodial surface anion channel (PSAC), a previously unexploited and highly conserved plasmodial target. Human malaria is caused by five species of protozoan parasites in the genus Plasmodium. It is estimated that there a ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Spread-deficient HCMV-vectored vaccines

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to establish human cytomegalovirus (HCMV) as a new human vaccine vector platform. In non-human primate models, CMV-vectored vaccines have shown unprecedented protection against immunodeficiency viruses and similar vaccines are currently being evaluated for their protective potential against a number of infectious diseases and cancer. ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of a novel antimalarial drug candidate for plant-scale synthesis

    SBC: DESIGNMEDIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about800 thousand deaths. Most of these deaths occur in sub-Saharan Africa among the more vulnerable groups, such as children and pregnant women. In a ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. A Blood Test for Pre-symptomatic Detection of Sepsis

    SBC: VIRTICI LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Each year, an estimated 1.7 million patients in the U.S. experience a hospital infection (CDC). Approximately 750,000 of these infections lead to severe sepsis, with over 200,000 patients dying [1]. As a result, 16 billion (40% of all intensive care unit expenditures) is spent each year managing patients with sepsis [1]. Sepsis is a potentially fatal conditi ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Screening for Inhibitors of TLR8 for Treatment of Rheumatoid Arthritis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Autoimmune diseases develop when the adaptive immune response targets self-antigens, leading to inflammation and tissue destruction. The innate immune system faces the same fundamental challenge as the adaptive immune system - distinguishing self from non-self antigens - and there is now considerable evidence that recognition of self nucleic acids through toll- ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a human pathogen that causes a wide range of diseases from skin and soft tissue infections (SSTI) to life threatening sepsis and pneumonia. Infections with S. aureus in the hospitals and community have been on the rise over the past two decades and the rapid spread of S. aureus strains resistant to methicilin (MRSA) and the last resort ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Beclomethasone post exposure therapy for gastrointestinal acute radiation syndrom

    SBC: Soligenix, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): This proposal concerns the use of beclomethasone dipropionate (BDP) as a post-exposure drug therapy having the potential to mitigate the gastrointestinal (GI) injury associated with acute radiation syndrome (ARS) following exposure to intense ionizing radiation. ARS occurs after toxic radiation exposure and involves at least several organ systems, primarily res ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government